Partner Headlines - MDVN

  1. 2 Biotech Funds Leading Nascent Bull Market: Which Is Right For ...

    Investors Business Daily
  2. Are Biotechs Finally Making A Comeback? Here Are 5 Must-Watch ...

    Investors Business Daily
  3. AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags

    Investors Business Daily
  4. Medivation Announces Fourth Quarter and Year-End 2015 Financial ...

    GuruFocus
  5. Microsoft, GoPro And 8 More Stocks To Watch Over The Weekend

    Benzinga
  6. Medivation to Present at Leerink Partners 5th Annual Global Healthcare ...

    GuruFocus
  7. Journal of Clinical Oncology Publishes Results From the STRIVE ...

    GuruFocus
  8. Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre

    GuruFocus
  9. Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial ...

    GuruFocus
  10. NanoString Technologies Enters Into Collaboration Agreement With ...

    GuruFocus
  11. Medivation to Present at J.P. Morgan Healthcare Conference

    GuruFocus
  12. Medivation Initiates Pivotal Clinical Trial of MDV9300 in Diffuse ...

    GuruFocus
  13. Wild Short Interest Swings For Three Top Biotech Stocks

    Benzinga
  14. Medivation Announces Third Quarter 2015 Financial Results Teleconference ...

    GuruFocus
  15. Medivation Announces Management Changes

    GuruFocus
  16. Medivation Effects a Stock Dividend on Its Common Stock

    GuruFocus
  17. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga
  18. A Portfolio To Support Cancer Treatments In Time For Prostate ...

    Benzinga
  19. Medivation Announces Participation at Upcoming Investor Conference

    GuruFocus
  20. Benzinga's Top Initiations

    Benzinga
  21. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    GuruFocus
  22. Benzinga's M&A Chatter for Monday August 24, 2015

    Benzinga
  23. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    Benzinga
  24. Benzinga's Top #PreMarket Gainers

    Benzinga
  25. Medivation Voted Three Years in a Row Among Top Workplaces in ...

    GuruFocus
  26. UPDATE: Medivation, Astellas Report Enrollment of First Patients ...

    Benzinga
  27. New Enzalutamide Data in Triple-Negative Breast Cancer Presented ...

    Benzinga
  28. Stocks: A Soft Jump On Jobs Data; WhiteWave, Boeing, NXP Climb

    IBD
  29. Top Drugmaker Profits Mixed

    IBD
  30. Medivation, Jazz Q1 Reports Miss; Regeneron Beats

    IBD
  31. Four Hot Stocks You'll Want To Keep On Your Radar

    IBD
  32. Nasdaq, S&P 500 Hang Tough; Avago, Akorn Big Earnings Winners

    IBD
  33. Medivation Tops Q4 Views On Strong Xtandi Results

    IBD
  34. Stocks Mixed; United Therapeutics Jumps To New High

    IBD
  35. Market Edges Higher, Unfazed By Weak HP Results

    IBD
  36. Market's Resilience Is Noteworthy; More Breakouts Emerge

    IBD
  37. Earnings Scheduled For February 25, 2015

    Benzinga
  38. Stocks Show Small Losses; Merger Talk Lifts Discovery

    IBD
  39. Stocks Quietly Lower; Domino's, Medivation Break Out

    IBD
  40. Wedbush Weighs in on Medivation Following Phase II TERRAIN Study ...

    GuruFocus
  41. Valeant Agrees To Buy Dendreon's Provenge

    IBD
  42. Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation ...

    GuruFocus
  43. Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically ...

    GuruFocus
  44. J&J Earnings Beat, But Sales, Guidance Miss Estimates

    IBD
  45. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  46. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  47. Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market

    Benzinga
  48. William Blair's Top BioPharmaceutical Stock Picks for Q1 2015

    GuruFocus
  49. Newly Profitable Medivation Riding High On Drug Sales

    IBD
  50. Chip Stocks, Biotechs Lead Another Nasdaq Rally

    IBD
  51. Major Upgrades And Downgrades In Friday's Market Action

    Benzinga
  52. Medivation Hits High After Q3 Earnings Beat

    IBD
  53. Medivation Hits High After Q3 Earnings Beat

    IBD
  54. Medivation and Astellas Announce Phase 3 Study of Enzalutamide ...

    GuruFocus
  55. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD
  56. Consider Medivation for Your Portfolio

    FoxBusiness
  57. Benzinga's Top Downgrades

    Benzinga
  58. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga
  59. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  60. Fast Money Halftime Report Final Trade From September 12

    Benzinga
  61. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  62. Stifel Raises Medivation Inc Price Target

    Benzinga
  63. Stocks Hitting 52-Week Highs

    Benzinga
  64. A Few Reasons Why Investors Should Consider Dendreon for Their ...

    GuruFocus
  65. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD
  66. Benzinga's Volume Movers

    Benzinga
  67. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  68. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  69. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  70. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  71. Benzinga's Top Upgrades

    Benzinga
  72. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  73. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  74. Morning Market Movers

    Benzinga
  75. Stocks To Watch For April 1, 2014

    Benzinga
  76. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  77. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  78. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  79. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  80. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  81. Benzinga's Top #PreMarket Losers

    Benzinga
  82. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  83. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  84. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  85. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  86. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  87. Stocks Hitting 52-Week Highs

    Benzinga
  88. Benzinga's Top #PreMarket Gainers

    Benzinga
  89. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  90. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  91. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  92. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  93. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  94. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  95. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  96. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  97. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  98. Benzinga's Top Initiations

    Benzinga
  99. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  100. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
Trading Center